Ingestible Capsule for GI Tract Pathology Detection

The patent introduces a radiotracer as an intermediary substance that binds to tumor-specific antigens. This radiotracer serves as a mediator between the tumor cells and the detection system, enabling sensitive detection of occult tumors that conventional methods cannot detect. The radiotracer accumulates at tumor sites, creating a detectable signal that bridges the gap between the tumor and the external detection apparatus.

The patent replaces mechanical visual examination methods (colonoscopy) with a nuclear medicine-based detection system. Instead of relying on mechanical insertion of scopes and visual inspection, the system uses radiotracer accumulation and gamma camera detection to identify tumors, substituting mechanical-diagnostic approaches with nuclear-physics-based detection that offers superior sensitivity for occult lesions.

The patent employs antibodies with high local specificity that bind only to tumor-specific antigens at the tumor site. This localized binding concentrates the radiotracer signal precisely where tumors are present, while normal tissues show minimal or no binding. The local quality of antibody-tumor antigen interaction creates high contrast between tumor and background, improving measurement precision despite the presence of background radiation.

The system allows preliminary accumulation of radiotracer in the bloodstream before imaging begins. By administering the radiotracer in advance and allowing time for circulation and tumor-specific accumulation, the system maximizes the tumor-to-background ratio before the actual imaging measurement is performed, thereby improving signal-to-background ratio.

The ingestible device is designed as a multi-functional platform that integrates multiple imaging modalities (nuclear radiation detection, optical fluorescence, infrared thermography, ultrasound, impedance sensing) within a single capsule. Each sensing module shares common structural elements such as the capsule housing, power source, and wireless communication system, allowing the device to perform diverse diagnostic functions without proportionally increasing overall complexity.

The device employs a nested structure where multiple sensing modules are housed within a single ingestible capsule. The capsule contains separate but integrated modules for different imaging modalities, with each module nested within the overall capsule structure. This nesting approach consolidates multiple functions into a compact form factor that can be swallowed as a single unit.

The ingestible device continuously performs diagnostic measurements throughout its entire transit through the gastrointestinal tract. Rather than requiring the device to stop or be retrieved for imaging, the system continuously collects data on nuclear radiation, optical fluorescence, infrared thermography, ultrasound, and impedance parameters as the capsule moves naturally through the GI tract, maximizing coverage without additional time loss.

The device utilizes the body's natural gastrointestinal peristalsis to propel itself through the tract, eliminating the need for external mechanical propulsion or patient intervention. The capsule performs self-powered transit and continuous self-diagnosis, automatically collecting and transmitting diagnostic data throughout its entire journey through the GI tract without requiring external control or stopping.